...
首页> 外文期刊>World Journal of Surgical Oncology >Successful resection of hepatocellular cancer not amenable to Milan criteria and durable complete remission induced by systemic polichemotherapy after development of metastases – should we think about revising the current treatment guidelines in selected patients?
【24h】

Successful resection of hepatocellular cancer not amenable to Milan criteria and durable complete remission induced by systemic polichemotherapy after development of metastases – should we think about revising the current treatment guidelines in selected patients?

机译:转移发生后,成功地切除不符合米兰标准的肝细胞癌和全身性策略化疗导致的持久完全缓解-我们是否应考虑修订某些患者的现行治疗指南?

获取原文

摘要

Objectives To refresh clinical diagnostic and therapeutic dilemmas in patients presenting with hepatocellular cancer (HCC) and to report a rare success of systemic polichemotherapy in metastatic HCC. Methods Case report of a patient with successfully resected HCC although initially deemed inoperable according to current guidelines, and who was successfully treated by systemic polichemotherapy after development of metastatic disease, resulting in a sustained complete remission. Results We describe a 71-year-old female with HCC initially treated by atypical liver resection, although not amenable to initial surgery according to current treatment guidelines, which resulted in 6?months disease-free interval. After development of pulmonary metastases, the patient was treated by systemic polichemotherapy, due to local unavailability of novel biologic agents. After 3?months of chemotherapy biochemical remission was confirmed, and after 10?months of active treatment complete radiological remission was verified according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, now exceeding 9?months in duration. Conclusion There is an increasing body of evidence that criteria for surgical interventions in HCC should be revised and expanded, and our case is an example of such an approach. Although novel biologic therapies are not widely available in all regions of the world due to their cost, currently there are no hard recommendations for use of chemotherapy in such areas. Since this is a large problem in clinical practice, we conclude that chemotherapy should be offered to selected patients of good performance status if novel agents are unavailable.
机译:目的刷新肝细胞癌(HCC)患者的临床诊断和治疗难题,并报告全身性策略化化疗在转移性HCC中的罕见成功。方法一名成功切除HCC的患者的病例报告,尽管最初根据当前指南被认为无法手术,但在转移性疾病发生后通过全身性策略化疗成功治疗,导致持续完全缓解。结果我们描述了一名71岁的HCC女性患者,尽管根据当前的治疗指南,该患者尽管不宜接受初次手术,但最初接受了非典型肝切除术,导致6个月无病间隔。发生肺转移后,由于局部无法使用新型生物制剂,因此对该患者进行了全身性政治化疗。化疗3个月后,生化缓解得到确认,积极治疗10个月后,根据实体瘤反应评估标准(RECIST)的标准验证了放射完全缓解,目前持续时间超过9个月。结论越来越多的证据表明,应修订和扩大HCC手术干预标准,我们的案例就是这种方法的一个例子。尽管由于成本高昂,新型生物疗法并未在世界所有地区广泛使用,但目前尚无在这些地区使用化学疗法的硬性建议。由于这在临床实践中是一个大问题,因此我们得出结论,如果无法使用新型药物,应为表现良好的特定患者提供化学疗法。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号